Trial Profile
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus First in man; Pharmacokinetics
- 21 Apr 2020 Status changed from recruiting to completed.
- 19 Sep 2018 New trial record